Amgen’s KRAS G12C Inhibitor Shows Deep, Durable Efficacy In Lung Cancer

 
• By Mandy Jackson
  
Pulmonology vector illustration
Amgen continues to explore monotherapy, combinations and biomarkers for sotorasib in lung cancer • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D